Nadecnemab is an investigational monoclonal antibody designed to target the GFRα3 receptor, which is involved in pain signaling pathways. Its primary application is in the development of treatments for chronic pain conditions, particularly those that are difficult to manage with conventional therapies. By binding selectively to GFRα3, nadecnemab aims to block the activity of artemin, a growth factor that contributes to pain sensitization. This mechanism offers potential for a non-opioid, non-addictive pain therapeutic, especially for patients with neuropathic or inflammatory pain. The antibody is being explored in clinical trials to evaluate its efficacy, safety, and long-term benefits in pain management.